Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014645
Filing Date
2023-08-11
Accepted
2023-08-11 16:05:30
Documents
50
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acxp-20230630x10q.htm   iXBRL 10-Q 1172361
2 EX-10.1 acxp-20230630xex10d1.htm EX-10.1 292141
3 EX-31.1 acxp-20230630xex31d1.htm EX-31.1 12638
4 EX-31.2 acxp-20230630xex31d2.htm EX-31.2 12643
5 EX-32.1 acxp-20230630xex32d1.htm EX-32.1 5510
6 EX-32.2 acxp-20230630xex32d2.htm EX-32.2 5548
  Complete submission text file 0001558370-23-014645.txt   4220117

Data Files

Seq Description Document Type Size
7 EX-101.SCH acxp-20230630.xsd EX-101.SCH 29579
8 EX-101.CAL acxp-20230630_cal.xml EX-101.CAL 17063
9 EX-101.DEF acxp-20230630_def.xml EX-101.DEF 110768
10 EX-101.LAB acxp-20230630_lab.xml EX-101.LAB 264350
11 EX-101.PRE acxp-20230630_pre.xml EX-101.PRE 205549
44 EXTRACTED XBRL INSTANCE DOCUMENT acxp-20230630x10q_htm.xml XML 400454
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40536 | Film No.: 231164006
SIC: 2834 Pharmaceutical Preparations